8647 Background: RET inhibitors (RETi) are currently the preferred first-line treatment in advanced RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Despite impressive efficacy of RETi, resistance is inevitable, and the optimal therapy beyond RETi remains unclear. Immunotherapy has shown limited efficacy in these patients. This study aims to investigate the impact of adding bevacizumab to chemotherapy regimens on treatment outcomes. Methods: This multicenter, retrospective study included patients with RET+ advanced NSCLC who received either a platinum-doublet chemotherapy (D) (+/-anti-PD-L(1) agents (ICB)) or a non-platinum monotherapy (M), with or without bevacizumab (Bev). Non-platinum agents were limited to pemetrexed, paclitaxel, or docetaxel. Only the first administration of the regimen was considered. Objective responses (OR), progression-free survival (PFS), and overall survival (OS) from the start of treatment were compared between patients receiving and not receiving Bev. Results: Of 185 patients, 20 received Bev in doublet chemotherapy (D+Bev, none with ICB) and 165 did not (D, 68 with ICB). Additionally, 40 underwent single-agent chemotherapy, with 8 on Bev (M+Bev) and 32 without (M). D+Bev patients were younger (median age: 54 vs. 61 years, p=0.026), less often treated with RETi (55% vs. 79%, p=0.023), with no other demographic or disease-related group differences. Both D+Bev and D had a median of 1 treatment line [IQR 1-1]. M+Bev and M had a median of 3 and 2 treatment lines, respectively (p=0.3), and numerically more M+Bev patients had brain metastases (25% vs. 13%, p=0.6). In the D+Bev vs D (+/-ICB) comparison, the OR was 55% vs 47% (p=0.7), and the median PFS was significantly longer in the D+Bev group (17 months vs. 8.8 months, p=0.018). When comparing D+Bev with D+ICB, D+Bev still showed a significant advantage in median PFS (17 months vs 9.7 months, p=0.05). The median OS was 51.4 months for D+Bev compared to 38.7 months for D (p=0.89). Multivariate analysis revealed that Bev use was independently associated with longer PFS (hazard ratio [HR] 0.4, p=0.01), while ECOG>1 (HR 4.3, p<0.0001) and male sex (HR 1.7, p=0.01) were associated with shorter PFS. In the M+Bev versus M group, the OR was 13% versus 25% (p=0.6), median PFS was 2.4 months versus 4.1 months (p=0.06), and median OS was 12.1 months versus 39 months (p=0.06). Conclusions: Bevacizumab with platinum-doublet chemotherapy seems to outperform platinum-doublet with or without ICB in progression-free survival. Prospective research is needed to evaluate the extent of bevacizumab's benefit for RET+ NSCLC.